FDA Authorizes First Neuromodulation Device for PTSD, but the Pivotal Trial Is Unpublished

Neurovalens's Modius Spero receives De Novo clearance for PTSD — a first in class that reaches the market with its pivotal efficacy data still in regulatory files, not peer-reviewed literature.

The FDA on June 19, 2026, authorized the Modius Spero device under the De Novo pathway as the first neurostimulation device to receive marketing authorization for posttraumatic stress disorder (PTSD) in the United States. The authorization grants a new device classification with special controls and creates a regulatory predicate for future 510(k) submissions targeting the same indication.

The Modius Spero applies transcutaneous electrical stimulation to the mastoid process — the bony prominence behind the ear — at parameters the manufacturer, Neurovalens, says modulate brainstem circuits connected to the autonomic nervous system and limbic system. The company’s rationale is that attenuating hyperarousal through this pathway can reduce PTSD symptom burden.

The pivotal evidence supporting the authorization has not been published in a peer-reviewed journal. The FDA’s decision was based on data submitted in the De Novo request, including a sham-controlled trial; the full trial report, protocol, and results are not available in the public scientific literature as of this edition. Neurovalens has indicated its intention to submit the data for publication, but no manuscript has appeared.

The absence of a published trial record is unusual for a first-in-class device authorization in a high-prevalence psychiatric indication. PTSD affects approximately 13 million Americans in any given year, according to the National Center for PTSD. Existing pharmacotherapy and psychotherapy options leave a substantial proportion of patients with inadequate symptom control — the unmet need is real. What is not yet independently verifiable is the magnitude of benefit the Modius Spero provides.

The FDA’s authorization letter specifies adjunctive use — not as a standalone treatment — and includes a post-market requirement for performance data within 36 months. Clinicians considering recommending the device should note that the primary efficacy evidence remains in regulatory files rather than the peer-reviewed record, and apply appropriate clinical judgment in that context.

FDA De Novo DEN240012, Neurovalens Modius Spero, June 19, 2026. National Center for PTSD, U.S. Dept. of Veterans Affairs.

Trace · every claim, sourced

Reported and written by Devices & Diagnostics Desk, then each load-bearing claim was bound to the primary source it rests on and checked out-of-band against that source before publication. The full mapping is below — nothing here is taken on faith.

The FDA on June 19, 2026, authorized the Modius Spero via De Novo pathway as the first neuromodulation device to receive marketing authorization for PTSD in the United States.

source on file

The pivotal efficacy evidence supporting the De Novo authorization has not been published in a peer-reviewed journal as of this edition.

source on file

PTSD affects approximately 13 million Americans in any given year, according to the National Center for PTSD.

source on file

After publication, a separate AI panel re-verifies every edition against these same sources. The running claim-confirmation rate and every correction are public on the accuracy ledger.